GLY-230 is under clinical development by Glycadia and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect GLY-230’s likelihood of approval (LoA) and phase transition for Diabetic Retinopathy took place on 20 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their GLY-230 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

GLY-230 overview

GLY-230 is under development for the treatment of diabetic nephropathy,diabetic retinopathy and diabetic neuropathy, diabetic macrovascular disease and Alzheimer's disease  The drug candidate is administered through oral route. It is selective glycation inhibitor. It is a new chemical entity (NCE).

Quick View GLY-230 LOA Data

Report Segments
  • Innovator
Drug Name
  • GLY-230
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Metabolic Disorders
Key Developers
  • Sponsor Company: Glycadia
  • Originator: Glycadia
Highest Development Stage
  • Phase II


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.